"We are pleased that we have succeeded in attracting new, high quality investors like Wellington Partners in our Series B round. This clearly signals backing from our investor community for the intended merger with Arpida."
Neil Goldsmith
CEO, Evolva
Wellington contact:
Erich Schlick
| Developing drugs with genetic chemistry |
Evolva uses its proprietary genetic chemistry platform to replicate on an industrial basis the ability of nature to create small molecules with exquisite design. Based on this technology, Evolva has a number of discovery and pre-clinical partnerships, which in 2008 generated revenues of about CHF 12 million. Evolva also has an attractive pipeline of drug candidates derived from this approach, among them an anti-fugal, an anti-viral and a compound for renal and cardiovascular disease. The combination of an extraordinary platform and exciting, novel products convinced Wellington Partners to co-lead a Series B round in autumn 2009 together with existing and other new investors. This financing round was also a prerequisite for the planned reverse merger with listed Swiss biotech company Arpida.
First investment: October 2009
Evolva SA
Hagmattstrasse 6
CH-4123 Allschwil
Switzerland
